HemOnc Today

CURRENTLY VIEWING:

The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Commentary

How the making of it matters

Christine Cserti-Gazdewich, MD, FRCPC

Adjunctive systemic therapy: A reasonable option for patients with muscle-invasive bladder cancer

Donald L. Trump, MD, FACP

City of Hope physician–researcher receives Ho-Am Prize in Medicine

Fox Chase announces staff appointments

ASH presents research training awards to seven fellows

Memorial Sloan Kettering Cancer Center names pediatrics chairman

Experts: Promotion of HPV vaccination must focus on cancer prevention

FDA’s cancer drug director to lead Oncology Center of Excellence

AACR president: ‘Full spectrum’ of cancer research must remain priority

Task force: Evidence insufficient to determine benefits, harms of routine screening pelvic exams

University of Maryland professor receives award for hyperthermic oncology research

Rutgers Cancer Institute appoints co-program leader

American Society for Radiation Oncology names honorary member

Cover Story

Immunotherapy, tumor profiling fill ‘gigantic knowledge gap’ in bladder cancer

Editorial

Word salad: What’s for dessert?

Derek Raghavan, MD, PhD

In the Journals

Obesity may increase risk for pediatric VTE

Meeting News Coverage

Local consolidative therapy prolongs PFS in patients with metastatic NSCLC

Many patients with terminal cancer receive aggressive end-of-life treatment

Liquid biopsy assay exhibits efficacy similar to traditional tumor biopsy

Palbociclib improves PFS in patients with HER-2–negative advanced breast cancer

Survey identifies perceived barriers to data sharing

Intraperitoneal chemotherapy after ovarian cancer surgery slows disease progression

Nilotinib induces treatment-free remission in patients with chronic phase CML

Pembrolizumab plus ipilimumab safe, effective for advanced melanoma

Plasma, urine genotyping effectively identify mutations in NSCLC

Preoperative chemoradiotherapy extends survival in esophagogastric junction adenocarcinoma

Novel therapy shows promise for advanced gastric cancer

Proton therapy may prolong OS in stage II, III NSCLC

PCP training improves skin cancer screening rates, diagnostic outcomes

Inotuzumab ozogamicin improves outcomes in adult ALL

Daratumumab combination improves PFS, ORR in relapsed, refractory multiple myeloma

Extended hormone therapy prolongs DFS, maintains quality of life

CPX-351 improves survival for older patients with high-risk secondary AML

Addition of capecitabine to adjuvant chemotherapy extends survival in pancreatic cancer

Biomarkers predict response to pembrolizumab in recurrent, metastatic HNSCC

Extended lymph node dissection may improve survival for patients with bladder cancer

Global variation in cancer drug prices does not reflect affordability

First-line atezolizumab demonstrates meaningful activity in patients with metastatic urothelial cancer

morganatic-roan